“Tenofovir Disoproxil Fumarate May Better Prevent Hepatocellular Carcinoma in Chronic Hepatitis B Patients than Entecavir: A Commentary on a Journal of Hepatology Study”

https://pubmed.ncbi.nlm.nih.gov/38115936

The abstract is a commentary on a study in the Journal of Hepatology that suggests tenofovir disoproxil fumarate may be more effective than entecavir in preventing hepatocellular carcinoma in patients with chronic hepatitis B, but notes the need for further research due to study limitations.